Prevalence of Extended Spectrum β-Lactamase and Antimicrobial Susceptibility Pattern of Clinical Isolates of Pseudomonas from Patients of Khyber Pakhtunkhwa, Pakistan

Table 5

In vitro (%) susceptibility of ESBL and non-ESBL produced by Pseudomonas spp.

Antimicrobials	⁢ESBL producers		⁢Non-ESBL producers		value
	Susceptible; (%)	Resistant; (%)	Susceptible; (%)	Resistant; (%)
AML	14 (9.5)	134 (90.5)	36 (19.4)	150 (80.6)	<0.018
AMC	24 (16.2)	124 (83.8)	58 (31.2)	128 (68.8)	0.0025
TZP	78 (52.7)	70 (47.3)	125 (67.2)	61 (32.8)	<0.01
SCF	76 (51.4)	72 (48.6)	155 (83.3)	31 (16.7)	<0.0001
CEC	21 (14.2)	127 (85.8)	50 (26.9)	136 (73.1)	<0.007
CAZ	30 (20.3)	118 (79.7)	81 (43.5)	105 (56.5)	<0.0001
CRO	22 (14.3)	126 (85.1)	99 (53.2)	87 (46.8)	<0.0001
FEP	33 (22.3)	115 (77.7)	129 (69.4)	57 (30.6)	<0.0001
SPX	62 (41.9)	86 (58.1)	124 (66.7)	62 (33.3)	<0.0001
CIP	55 (37.2)	93 (62.8)	113 (60.8)	73 (39.2)	<0.0001
ENX	43 (29.1)	105 (70.9)	74 (39.8)	112 (60.2)	<0.05
GTX	55 (37.2)	93 (62.8)	94 (50.5)	92 (49.5)	<0.01
MXF	80 (54.1)	68 (45.9)	116 (62.4)	70 (37.6)	<0.13
E	36 (24.3)	112 (75.7)	28 (15.1)	158 (84.9)	<0.325
CLR	66 (44.6)	80 (54.1)	76 (40.9)	110 (59.1)	<0.43
MEM	128 (86.5)	20 (13.5)	176 (94.6)	10 (5.4)	<0.0098
IPM	120 (81.1)	28 (18.9)	172 (92.5)	14 (7.5)	<0.0018
CN	20 (13.5)	128 (86.5)	42 (22.6)	144 (77.4)	<0.034
AK	75 (50.7)	73 (49.3)	141 (75.8)	45 (24.2)	<0.0001
DO	9 (6.1)	139 (93.9)	25 (13.4)	161 (86.6)	<0.0426